On a deal spree, Take­da part­ners up with Nek­tar on a slate of can­cer R&D com­bo stud­ies

Take­da con­tin­ues its pipeline re­vamp with a new deal to col­lab­o­rate with Nek­tar Ther­a­peu­tics on a slate of new com­bo stud­ies us­ing its lead im­muno-on­col­o­gy can­di­date, NK­TR-214.

The deal calls for the two com­pa­nies to share the costs of re­search and con­tribute the drugs to the part­ner­ship, much like Nek­tar’s ear­li­er deal with Bris­tol-My­ers Squibb. Take­da has been busi­ly out­li­cens­ing, in­li­cens­ing and buy­ing prod­ucts to re­make its pipeline, with a big fo­cus on boost­ing the can­cer R&D work in their Boston hub.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER